208 related articles for article (PubMed ID: 30549487)
1. Early Placebo Improvement Is a Marker for Subsequent Placebo Response in Long-Acting Injectable Antipsychotic Trials for Schizophrenia: Combined Analysis of 4 RCTs.
Kumagai F; Suzuki T; Fleischhacker WW; Yasui-Furukori N; Mimura M; Uchida H
J Clin Psychiatry; 2018 Dec; 80(1):. PubMed ID: 30549487
[TBL] [Abstract][Full Text] [Related]
2. Placebo effects in adult and adolescent patients with schizophrenia: combined analysis of nine RCTs.
Kubo K; Fleischhacker WW; Suzuki T; Yasui-Furukori N; Mimura M; Uchida H
Acta Psychiatr Scand; 2019 Feb; 139(2):108-116. PubMed ID: 30198163
[TBL] [Abstract][Full Text] [Related]
3. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
Hough D; Gopal S; Vijapurkar U; Lim P; Morozova M; Eerdekens M
Schizophr Res; 2010 Feb; 116(2-3):107-17. PubMed ID: 19959339
[TBL] [Abstract][Full Text] [Related]
4. Extended-release intramuscular paliperidone palmitate: a review of its use in the treatment of schizophrenia.
Carter NJ
Drugs; 2012 May; 72(8):1137-60. PubMed ID: 22571444
[TBL] [Abstract][Full Text] [Related]
5. Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia.
Ascher-Svanum H; Zhao F; Detke HC; Nyhuis AW; Lawson AH; Stauffer VL; Montgomery W; Witte MM; McDonnell DP
BMC Psychiatry; 2011 Sep; 11():152. PubMed ID: 21943257
[TBL] [Abstract][Full Text] [Related]
6. Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial.
Bossie CA; Sliwa JK; Ma YW; Fu DJ; Alphs L
BMC Psychiatry; 2011 May; 11():79. PubMed ID: 21569242
[TBL] [Abstract][Full Text] [Related]
7. A prospective flexible-dose study of paliperidone palmitate in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agents.
Schreiner A; Bergmans P; Cherubin P; Keim S; Rancans E; Bez Y; Parellada E; Carpiniello B; Vidailhet P; Hargarter L
Clin Ther; 2014 Oct; 36(10):1372-88.e1. PubMed ID: 25444566
[TBL] [Abstract][Full Text] [Related]
8. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia.
Lauriello J; Lambert T; Andersen S; Lin D; Taylor CC; McDonnell D
J Clin Psychiatry; 2008 May; 69(5):790-9. PubMed ID: 18452346
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
Li H; Rui Q; Ning X; Xu H; Gu N
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
[TBL] [Abstract][Full Text] [Related]
10. Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence.
Si T; Li N; Lu H; Cai S; Zhuo J; Correll CU; Zhang L; Feng Y
J Psychopharmacol; 2018 Jun; 32(6):691-701. PubMed ID: 29764266
[TBL] [Abstract][Full Text] [Related]
11. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
[TBL] [Abstract][Full Text] [Related]
12. Intramuscular paliperidone palmitate.
Hoy SM; Scott LJ; Keating GM
CNS Drugs; 2010 Mar; 24(3):227-44. PubMed ID: 20155997
[TBL] [Abstract][Full Text] [Related]
13. Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics.
Kwon JS; Kim SN; Han J; Lee SI; Chang JS; Choi JS; Lee HJ; Cho SJ; Jun TY; Lee SH; Han C; Lee KU; Lee KK; Lee E
Int Clin Psychopharmacol; 2015 Nov; 30(6):320-8. PubMed ID: 26196188
[TBL] [Abstract][Full Text] [Related]
14. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia.
Schreiner A; Aadamsoo K; Altamura AC; Franco M; Gorwood P; Neznanov NG; Schronen J; Ucok A; Zink M; Janik A; Cherubin P; Lahaye M; Hargarter L
Schizophr Res; 2015 Dec; 169(1-3):393-399. PubMed ID: 26431793
[TBL] [Abstract][Full Text] [Related]
15. Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics.
Hargarter L; Cherubin P; Bergmans P; Keim S; Rancans E; Bez Y; Parellada E; Carpiniello B; Vidailhet P; Schreiner A
Prog Neuropsychopharmacol Biol Psychiatry; 2015 Apr; 58():1-7. PubMed ID: 25448776
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of once-monthly paliperidone palmitate long-acting injection in an elderly patient with schizophrenia.
Rama Raj P; Lewis M; Macfarlane S
BMJ Case Rep; 2015 Aug; 2015():. PubMed ID: 26311017
[TBL] [Abstract][Full Text] [Related]
17. Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2012 Jun; 73(6):856-64. PubMed ID: 22687813
[TBL] [Abstract][Full Text] [Related]
18. Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial.
Takekita Y; Koshikawa Y; Fabbri C; Sakai S; Sunada N; Onohara A; Nishida K; Yoshimura M; Kato M; Serretti A; Kinoshita T
BMC Psychiatry; 2016 May; 16():172. PubMed ID: 27236412
[TBL] [Abstract][Full Text] [Related]
19. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study.
Savitz AJ; Lane R; Nuamah I; Gopal S; Hough D
J Am Acad Child Adolesc Psychiatry; 2015 Feb; 54(2):126-137.e1. PubMed ID: 25617253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]